Kura Oncology stock holds at USD 11.73 as Caspian launches

Published on 09/23/2026 at 13:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kura Oncology stock closed at USD 11.73 on September 23, 2026, while fair value was estimated at USD 31.17. Caspian raised USD 50 million.

KURA, US50126D1028, Illustration mit AI erstellt.

Kura Oncology, Inc. (US50126D1028) closed at USD 11.73 on Nasdaq on September 23, 2026, with the stock up 1.12 percent in the latest quoted market snapshot. The company is also being valued against a USD 31.17 narrative fair-value estimate as its Caspian venture develops.

Caspian adds a second pipeline angle

According to Simply Wall St on September 23, 2026, Kura contributed its KO-7246 menin inhibitor program and related intellectual property to Caspian Therapeutics in exchange for equity, a reimbursement payment of up to USD 1.5 million and continuing collaboration services.

Caspian was backed by a USD 50 million raise, giving the transaction a concrete financing reference alongside Kura's oncology program. The structure broadens the potential use of the company's menin-inhibitor platform beyond oncology, but it also leaves future value dependent on development and approval execution.

Approval timing drives the valuation gap

The same September 23, 2026 report places Kura's expected ziftomenib approval and commercial launch in relapsed or refractory NPM1-mutant acute myeloid leukemia at the center of the valuation case. It also describes two planned Phase III frontline AML trials under KOMET-017 and an addressable market estimated at more than USD 7 billion annually if those programs succeed.

The valuation spread is substantial: the USD 31.17 narrative fair-value estimate is USD 19.44 above the USD 11.73 close, or 165.7 percent higher. That comparison is an analytical scenario rather than a company forecast, and the report identifies future approvals and pipeline execution as the decisive conditions.

Stock closes at USD 11.73

Kura Oncology stock stood at USD 11.73 on Nasdaq on September 23, 2026, compared with the previous close implied by the quoted 1.12 percent daily gain. The market snapshot provides the clearest same-day reference while the Caspian financing and ziftomenib launch expectations define the current valuation debate.